Trial reportInternational journal of clinical pharmacy2011
Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD.
Trial report in International journal of clinical pharmacy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Self-management interventions for people with chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2022Pooled it
- Integrated disease management interventions for patients with chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2021Pooled it
- Can self-management programmes change healthcare utilisation in COPD?: A systematic review and framework analysis.Patient education and counseling · 2021Pooled it
- Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2016Pooled it
- Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.International journal of clinical pharmacy · 2014Pooled it
- Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations.PharmacoEconomics · 2013Pooled it
- A Smartphone App Self-Management Program for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial of Clinical Outcomes.JMIR mHealth and uHealth · 2025Trial
- Trial
- Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Respiratory research · 2014Trial
- Evaluation of a Tailored Multifaceted Pharmaceutical Care Intervention to Optimize Chronic Obstructive Pulmonary Disease Management: Protocol for a Cluster Randomized Controlled Trial.JMIR research protocols · 2026Article
- A Digital, Self-Management Behavior Change Intervention for People With Chronic Obstructive Pulmonary Disease: Cohort Study.JMIR formative research · 2025Article
- Inhalation Innovation: Optimizing COPD Care Through Clinical Pharmacist Integration in a Rehabilitation Hospital's Multidisciplinary Team - A Quality Improvement Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Cost savings associated with a web-based physical activity intervention for COPD.The American journal of managed care · 2022Article
- Article
- General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial.Journal of pharmaceutical policy and practice · 2021Article
- Cost-Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy.Patient preference and adherence · 2021Article
- Impact of clinical pharmacist-led diabetes management clinic on health outcomes at an academic hospital in Riyadh, Saudi Arabia: A prospective cohort study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.Medical decision making : an international journal of the Society for Medical Decision Making · 2020Article
Corrections and comments
- Erratum issuedElnay, James C [corrected to McElnay, James C]
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo undertake a cost-utility analysis (CUA) of a pharmacy-led self-management programme for Chronic Obstructive Pulmonary Disease (COPD).
settingA single outpatient COPD clinic at the Mater Hospital, Belfast, Northern Ireland between.
methodCUA alongside a randomised control trial. The economic analysis used data from 127 COPD patients aged over 45 years, with an FEV1 of 30-80% of the predicted normal value. Participants received either a pharmacy-led education and self-management programme, or usual care. One year costs were estimated from the perspective of the National Health Service and Personal Social Services and quality-adjusted life years (QALYs) were calculated based on responses to the EQ-5D at baseline, 6 and 12 months.
main outcome measureCost per QALY gained.
resultsThe mean differences in costs and effects between the self-management and education programme and usual care were -£671.59 (95 CI%: -£1,584.73 to -£68.14) and 0.065 (95% CI; 0.000-0.128). Thus the intervention was the dominant strategy as it was both less costly and more effective than usual care. The probability of the intervention being cost-effective was 95% at a threshold of £20,000/QALY gained. Sensitivity analyses indicated that conclusions were robust to variations in most of the key parameters.
conclusionThe self-management and education programme was found to be highly cost-effective compared to usual care. Further research is required to establish what aspects of self-management and education programmes have the greatest impact on cost-effectiveness.
Indexed as
Identifiers
21643784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.